1544P Use of pharmacokinetic parameters of preoperative 5-FU as a prognostic factor in resected pancreatic cancer

Neoadjuvant therapy is an increasingly used approach in patients with resectable pancreatic cancer (PC). A positive link between chemotherapy dose intensity and patients’ outcome has been suggested in other PC settings. The aim of this study was to assess whether 5-FU pharmacokinetic (PK) parameters correlate with outcome in resected PC patients treated with preoperative FOLFOXIRI. From January 2012 to November 2019 patients with potentially...